117 related articles for article (PubMed ID: 30770236)
1. Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report.
Erikson AK; Yu NY; Sheedy JT; Shoudis SN; Paripati HR; Sio TT
Pract Radiat Oncol; 2019 May; 9(3):128-131. PubMed ID: 30770236
[No Abstract] [Full Text] [Related]
2. Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma.
Nakashima T; Nonoshita T; Hirata H; Inoue K; Nagashima A; Yoshitake T; Asai K; Shioyama Y
In Vivo; 2020; 34(1):247-253. PubMed ID: 31882485
[TBL] [Abstract][Full Text] [Related]
3. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Yang H; He D; Wang F; Deng Q; Xie Z
Clin Exp Metastasis; 2020 Jun; 37(3):391-399. PubMed ID: 32356218
[TBL] [Abstract][Full Text] [Related]
4. Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
Pongcharoen P; Chanprapaph K; Vachiramon V
Arch Dermatol; 2011 Jun; 147(6):735-40. PubMed ID: 21690542
[No Abstract] [Full Text] [Related]
5. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
[No Abstract] [Full Text] [Related]
7. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
9. Lung Adenocarcinoma Metastasis to the Prostate: A Case Report.
Gilmour N; Mampuya WA; Jumeau R; Dattner N; Ozsahin M
Pract Radiat Oncol; 2019 Mar; 9(2):77-80. PubMed ID: 30832805
[No Abstract] [Full Text] [Related]
10. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Kau HC; Tsai CC
Cutan Ocul Toxicol; 2016 Sep; 35(3):257-9. PubMed ID: 26340340
[TBL] [Abstract][Full Text] [Related]
12. Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Yamanaka Y; Sekine A; Kato T; Yamakawa H; Ikeda S; Baba T; Iwasawa T; Okudela K; Ogura T
Intern Med; 2017 Nov; 56(21):2895-2898. PubMed ID: 28943548
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
[No Abstract] [Full Text] [Related]
14. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.
Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J
Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
16. Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
Liu Y; Jiang X; Gu Y; Chen Y
Int Immunopharmacol; 2019 Apr; 69():79-87. PubMed ID: 30682720
[TBL] [Abstract][Full Text] [Related]
17. Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Walther JC; Khorshid M; Gaya A; Plowman PN
Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):637-9. PubMed ID: 17051957
[No Abstract] [Full Text] [Related]
18. Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient.
Hecimovic A; Vukic Dugac A; Jankovic Makek M; Cikes M; Samarzija M; Jakopovic M
Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31315351
[TBL] [Abstract][Full Text] [Related]
19. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach.
Parlak C; Mertsoylu H; Güler OC; Onal C; Topkan E
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):885-91. PubMed ID: 24495594
[TBL] [Abstract][Full Text] [Related]
20. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
